Awaiting development: Guidance and quality standards

Showing 161 to 170 of 362

Guidance and quality standards awaiting development
Title	Type
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]	Technology appraisal guidance
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]	Technology appraisal guidance
Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]	Technology appraisal guidance
Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]	Technology appraisal guidance
Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]	Technology appraisal guidance
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]	Technology appraisal guidance